SCHEDULE 13G: BlackRock Discloses 6.9% Passive Stake in CRISPR Therapeutics AG
Beneficial Ownership Disclosure
BlackRock, Inc. has filed a Schedule 13G, reporting a passive beneficial ownership of 6.9% of the common stock of CRISPR Therapeutics AG as of June 30, 2025.
Summary
- BlackRock, Inc. reported beneficial ownership of 5,932,433 shares of common stock in CRISPR Therapeutics AG.
- This ownership represents 6.9% of the total outstanding common stock of CRISPR Therapeutics AG.
- BlackRock holds sole voting power over 5,766,693 shares and sole dispositive power over 5,932,433 shares.
- The filing indicates that the shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
- Several BlackRock subsidiaries, including BlackRock Investment Management, LLC, are noted as beneficially owning shares, with BlackRock Investment Management, LLC owning 5% or greater of the outstanding shares.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing disclosing a passive ownership stake, providing factual information without expressing positive or negative sentiment regarding the issuer's performance or outlook.
Future Outlook
NA
Industry Context
This Schedule 13G filing indicates a significant passive investment by BlackRock, one of the world's largest asset managers, in CRISPR Therapeutics AG, a company operating in the biotechnology and gene editing sector. Such filings are routine disclosures for institutional investors holding more than 5% of a company's shares, signaling a long-term, non-controlling interest in the company's growth prospects within its industry.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional holding, potentially signaling confidence from a major asset manager.
- Investment Community: Offers insight into institutional investment trends in the biotechnology sector.
Key Dates
| Date | Description |
|---|---|
| 01/21/2025 | Date of execution of the Power of Attorney by BlackRock, Inc. |
| 06/30/2025 | Date of event which requires the filing of this statement. |
| 07/17/2025 | Date of filing of the Schedule 13G by BlackRock, Inc. |
Keywords
CRISPR Therapeutics AG, BlackRock Inc., Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Passive Investment, Biotechnology, Gene Editing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.